The China Honeymoon Is Over: Global Medtech Must Think Decisively

It Should Be No Surprise That The Challenge Of China Will Only Ratchet Up Further

19 Jul 2022

China is transitioning to an economy driven by innovation and technology, with differential effects on foreign medtechs depending on their place in the value chain and type of innovation. China commentators have been updating the market.

Market entry in China and the conditions for competing locally are becoming incrementally harder for foreign medtech innovators seeking to serve fast-growing patient demand in a population of 1.439 billion people (in 2020, sourced from OECD on 6 July 2022).

Foreign companies with mainstream medtech offerings can expect market access in China to become more and more difficult, according to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

19 Jun 2025

• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

18 Jun 2025

• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist